Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Phase: N/A Priority: Normal
NCT ID: NCT06443944 Org: User:
Start: - End: - Due: -

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Phase: N/A Priority: Normal
NCT ID: NCT06567743 Org: User:
Start: 09/16/24 End: 12/30/27 Due: 12/30/28

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

Phase: N/A Priority: Normal
NCT ID: NCT04387461 Org: User:
Start: 12/08/20 End: 05/28/24 Due: 05/28/25

Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure

Phase: N/A Priority: Normal
NCT ID: NCT02365818 Org: User:
Start: 06/02/15 End: 02/28/19 Due: 02/28/20

Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01438112 Org: User:
Start: 03/31/14 End: 06/30/16 Due: 06/30/17

Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02143804 Org: User:
Start: 03/31/14 End: 03/31/15 Due: 03/31/16

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Phase: N/A Priority: Normal
NCT ID: NCT04452591 Org: User:
Start: 10/27/20 End: 12/24/29 Due: 12/24/30

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Phase: N/A Priority: Normal
NCT ID: NCT06111235 Org: User:
Start: 12/14/23 End: 01/31/30 Due: 01/31/31